IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion - Chan, Li-Chuan; Li, Chia-Wei; Xia, Weiya; Hsu, Jung-Mao; Lee, Heng-Huan; Cha, Jong-Ho; Wang, Hung-Ling; Yang, Wen-Hao; Yen, Er-Yen; Chang, Wei-Chao; Zha, Zhengyu; Lim, Seung-Oe; et al. (The Journal of clinical investigation, 2019)
Keywords: Animal models; Animals; Antibodies; Apoptosis; B7-H1 Antigen - immunology; Biomedical research; Cancer; Carcinoma; Cell activation; Cell growth; Cell Line, Tumor; Chemokines; Cytokines; Endoplasmic reticulum; FDA approval; Federal regulation; Gene expression; Glycosylation; Glycosyltransferase; Growth factors; Hepatocellular carcinoma; Humans; Immune evasion; Immunoglobulins; Immunosuppression; Immunosurveillance; Immunotherapy; Intelligence gathering; Interleukin 6; Interleukin-6 - immunology; Janus kinase; Janus Kinase 1 - immunology; Kinases; Ligands; Liver cancer; Lymphocytes; Lymphocytes T; Male; Medical prognosis; Mice; Mucin; Mutation; Neoplasm Proteins - immunology; Neoplasms, Experimental - immunology; Neoplasms, Experimental - pathology; Neoplasms, Experimental - therapy; Nivolumab; Patients; PD-L1 protein; Phosphorylation; Protein expression; Protein Stability; Proteins; Regorafenib; Response rates; Ruxolitinib; Signal Transduction - immunology; Siltuximab; Sorafenib; T cell receptors; T cells; Tocilizumab; Tumor Escape; Tumors; South Korea; Texas; China; Liver cancer; Oncology; Cancer immunotherapy; Cell Biology